IPO - Merus N.V.

Form Type: 424B5

Filing Date: 2025-06-05

Corporate Action: Ipo

Type: New

Accession Number: 000119312525135275

Filing Summary: Merus N.V. is offering 5,263,158 common shares, listed on The Nasdaq Global Market under the symbol 'MRUS.' As of June 3, 2025, the last reported sale price was $62.42 per share. The public offering price is set at $57.00 per share, totaling approximately $300 million. After deducting underwriting discounts and commissions, the proceeds to the company before expenses amount to approximately $282 million. The underwriters have a 30-day option to purchase an additional 789,473 shares, which could increase total proceeds if exercised. The shares are expected to be delivered on June 5, 2025. The offering aims to advance clinical development of their product candidates and for general corporate purposes. Investors are warned of significant risks involved with the investment and should consider various risk factors outlined in detail later in the document.

Form Type: 8-K

Filing Date: 2025-06-05

Corporate Action: Ipo

Type: New

Accession Number: 000119312525135033

Filing Summary: On June 3, 2025, Merus N.V. entered into an underwriting agreement with multiple underwriters for a public offering of 5,263,158 common shares at a price of $57.00 per share, expected to close on June 5, 2025. The company aims to raise approximately $281.7 million from the offering to fund the clinical development of its product candidates, preclinical research, and for general corporate purposes. The underwriting agreement includes a 30-day option for underwriters to purchase an additional 789,473 shares. Legal counsel has provided an opinion regarding the validity of the securities to be sold.